{
    "root": "351f1ba0-8015-9455-e063-6294a90a17a3",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Allopurinol",
    "value": "20250514",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "ALLOPURINOL",
            "code": "63CZ7GJN5I"
        }
    ],
    "indications": "allopurinol tablets indicated : management adults signs symptoms primary secondary gout ( acute attacks , tophi , joint destruction , uric acid lithiasis , and/or nephropathy ) management adult pediatric patients leukemia , lymphoma solid tumor malignancies receiving cancer therapy causes elevations serum urinary uric acid levels management adult patients recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day male patients 750 mg/day female patients , despite lifestyle changes ( reduction dietary sodium , non-dairy animal protein , oxylate rich foods , refined sugars increases oral fluids fruits vegetables ) limitations allopurinol tablets recommended treatment asymptomatic hyperuricemia .",
    "contraindications": "gout : prior initiating treatment assess serum uric acid level , complete blood count , chemistry panel , liver kidney function tests . prophylactic treatment gout flares recommended . ( 2.1 , 2.2 ) patients normal kidney function : initial 100 mg orally daily . increase 100 mg weekly increments serum uric acid 6 mg/dl less reached ( maximum 800 mg daily ) . ( 2.3 ) patients impaired kidney function : initial 50 mg orally daily . follow recommendations titration patients renal impairment target serum uric acid level reached . ( 2.6 ) complete information full prescribing information ( fpi ) . hyperuricemia associated cancer therapy : recommended : adults : 300 mg 800 mg orally daily . pediatric patients : 100 mg/m 2 orally every 8 hours 12 hours ( 10 mg/kg/day , maximum 800 mg/day ) complete information fpi . ( 2.4 , 2.6 ) recurrent calcium oxalate calculi : recommended initial patients normal kidney function 200 mg 300 mg orally daily . ( 2.5 ) patients renal impairment : fpi modifications patients renal impairment . ( 2.6 )",
    "warningsAndPrecautions": "supplied allopurinol tablets , usp available follows : 100 mg tablets white off-white , round , flat , beveled , uncoated tablets debossed `` 349 `` breakline , `` u `` breakline one side plain side . available : unit dose packages 100 ( 10x10 ) ndc 60687-677-01 300 mg tablets white off-white , round , flat , beveled , uncoated tablets debossed `` 350 `` breakline , `` u `` breakline one side plain side . available : unit dose packages 100 ( 10x10 ) ndc 60687-688-01 storage handling store 20°c 25°c ( usp controlled room temperature ) ( 68°f 77°f ) dry place . protection : blister torn broken .",
    "adverseReactions": "allopurinol tablets contraindicated patients history hypersensitivity reaction allopurinol ingredients allopurinol tablets .",
    "indications_original": "Allopurinol tablets are indicated for:\n                  \n                     The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy)\n                     The management of adult and pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels\n                     The management of adult patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients, despite lifestyle changes (such as reduction of dietary sodium, non-dairy animal protein, oxylate rich foods, refined sugars and increases in oral fluids and fruits and vegetables)\n                  \n                  \n                     Limitations of Use\n                     \nAllopurinol tablets are not recommended for the treatment of asymptomatic hyperuricemia.",
    "contraindications_original": "Gout : Prior to initiating treatment assess serum uric acid level, complete blood count, chemistry panel, liver and kidney function tests. Prophylactic treatment for gout flares is recommended. ( 2.1 , 2.2 ) Patients with normal kidney function: Initial dosage is 100 mg orally daily. Increase by 100 mg weekly increments until serum uric acid of 6 mg/dl or less is reached (maximum 800 mg daily). ( 2.3 ) Patients with impaired kidney function: The initial dosage is 50 mg orally daily. Follow recommendations for titration in patients with renal impairment until target serum uric acid level is reached. ( 2.6 ) See complete information in the Full Prescribing Information (FPI). Hyperuricemia Associated with Cancer Therapy : The recommended dosage is: Adults: 300 mg to 800 mg orally daily. Pediatric patients: 100 mg/m 2 orally every 8 hours to 12 hours (10 mg/kg/day, maximum 800 mg/day) See complete information in the FPI. ( 2.4 , 2.6 ) Recurrent Calcium Oxalate Calculi : The recommended initial dosage in patients with normal kidney function is 200 mg to 300 mg orally daily. ( 2.5 ) Dosage in Patients with Renal Impairment: See FPI for dosage modifications in patients with renal impairment. ( 2.6 )",
    "warningsAndPrecautions_original": "How Supplied\n                     \nAllopurinol tablets, USP are available as follows:\n  \nThe 100 mg tablets are white to off-white, round, flat, beveled, uncoated tablets debossed with \"349\" above breakline, \"U\" below breakline on one side and plain on the other side. They are available as:\n  \nUnit dose packages of 100 (10x10) NDC 60687-677-01\n \n                  The 300 mg tablets are white to off-white, round, flat, beveled, uncoated tablets debossed with \"350\" above breakline, \"U\" below breakline on one side and plain on the other side. They are available as:\n  \nUnit dose packages of 100 (10x10) NDC 60687-688-01\n \n                  \n                     Storage and Handling\n                     \nStore at 20°C to 25°C (USP Controlled Room Temperature) (68°F to 77°F) in a dry place.\n  \n                     FOR YOUR PROTECTION: Do not use if blister is torn or broken.",
    "adverseReactions_original": "Allopurinol tablets are contraindicated in patients with a history of hypersensitivity reaction to allopurinol or to any of the ingredients of allopurinol tablets."
}